Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AGIO 
Agios Pharm (AGIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: AGIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $47.67
1 Year Target Price $47.67
| 3 | Strong Buy |
| 3 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.46% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.06B USD | Price to earnings Ratio 3.13 | 1Y Target Price 47.67 |
Price to earnings Ratio 3.13 | 1Y Target Price 47.67 | ||
Volume (30-day avg) 9 | Beta 0.8 | 52 Weeks Range 23.41 - 62.58 | Updated Date 08/13/2025 |
52 Weeks Range 23.41 - 62.58 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 11.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate -1.81 | Actual -1.93 |
Profitability
Profit Margin 1590.42% | Operating Margin (TTM) -1020.12% |
Management Effectiveness
Return on Assets (TTM) -25.71% | Return on Equity (TTM) 64.05% |
Valuation
Trailing PE 3.13 | Forward PE 2.47 | Enterprise Value 1165454706 | Price to Sales(TTM) 50.29 |
Enterprise Value 1165454706 | Price to Sales(TTM) 50.29 | ||
Enterprise Value to Revenue 28.51 | Enterprise Value to EBITDA -2.33 | Shares Outstanding 58101500 | Shares Floating 51431464 |
Shares Outstanding 58101500 | Shares Floating 51431464 | ||
Percent Insiders 1.66 | Percent Institutions 107.39 |
Upturn AI SWOT
Agios Pharm
Company Overview
History and Background
Agios Pharmaceuticals, founded in 2008, focused initially on cancer metabolism before expanding into rare genetic diseases. Key milestones include the FDA approvals of Tibsovo and Pyrukynd.
Core Business Areas
- Oncology: Development and commercialization of therapies targeting cancer metabolism.
- Rare Genetic Diseases: Development and commercialization of therapies for rare genetic diseases, particularly pyruvate kinase deficiency.
Leadership and Structure
The leadership team includes the CEO, CFO, and heads of research and development. The organizational structure is typical of a biopharmaceutical company, with departments focused on research, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- Pyrukynd (mitapivat): Pyrukynd is an oral allosteric activator of the RBC PK enzyme for pyruvate kinase (PK) deficiency. As of 2023, it held a significant portion of market share in PK deficiency treatments. Competitors: None with the same mechanism of action; supportive care and potential future gene therapies are alternatives. Revenue in 2023 was $130 million.
- Tibsovo (ivosidenib): Tibsovo is an oral targeted therapy for acute myeloid leukemia (AML) with an IDH1 mutation. Tibsovo is now part of Servier's portfolio. Competitors: Enasidenib (Idhifa), chemotherapy, and other targeted therapies. Market share is relevant to the proportion of AML patients with IDH1 mutations.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory scrutiny, and competition. Recent trends include a focus on precision medicine and gene therapies.
Positioning
Agios is positioned as a leader in the development of therapies for rare genetic diseases and specific cancers, leveraging its expertise in cellular metabolism.
Total Addressable Market (TAM)
The TAM for Agios's current portfolio is estimated at several billion dollars, including PK deficiency and IDH1-mutated AML. Agios is positioned to capture a significant share of this market with its approved therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- FDA-approved products
- Strong expertise in rare genetic diseases
- Solid financial position
Weaknesses
- Reliance on a limited number of products
- Competition from larger pharmaceutical companies
- High R&D expenses
- Regulatory hurdles
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships
- Acquisition of new technologies
- Further clinical development of existing products
Threats
- Generic competition
- Clinical trial failures
- Changes in regulatory landscape
- Economic downturn
Competitors and Market Share
Key Competitors
- SNY
- MRK
- BMY
Competitive Landscape
Agios competes with larger pharmaceutical companies in certain therapeutic areas. Its competitive advantages include its expertise in rare genetic diseases and its novel therapeutic approaches. Sanofi, Merck, and Bristol Myers Squibb are competitors in the broader oncology space and potentially overlapping indications or future therapies.
Major Acquisitions
None
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Agios's growth has been driven by the commercial success of Pyrukynd.
Future Projections: Analysts project continued revenue growth for Pyrukynd and expansion into new indications. Future growth depends on successful clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives include expanding the indications for Pyrukynd and investing in research and development of new therapies.
Summary
Agios Pharm is a biopharmaceutical company focused on rare genetic diseases and oncology with an FDA-approved product Pyrukynd that increases revenue. Its financial position is solid, but reliance on a limited number of products is a risk. Expansion into new therapeutic areas and strategic partnerships are key to future growth. Competition from larger pharmaceutical companies remains a significant challenge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Agios Pharmaceuticals Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates and is for informational purposes only. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agios Pharm
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2013-07-24 | CEO & Director Mr. Brian M. Goff M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 486 | Website https://www.agios.com |
Full time employees 486 | Website https://www.agios.com | ||
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.